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Serotonin Belcher 
Abstract 
Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for 
endogenous depression. In addition to depleting the nerve terminals of 
serotonin they also lower blood platelet serotonin levels. Platelet aggregation 
is a major component of acute coronary syndromes, including sudden death, 
and also of limb ischaemia. Platelet-released serotonin causes constriction of 
diseased blood vessels. The recent literature has revealed a number of 
reports of association between treatment of depression with SSRIs and 
reduced events caused by intra-arterial thrombosis.  The effects of serotonin 
and serotonin depletion upon intracoronary thrombosis, diseased blood 
vessels, blood platelets and bleeding are discussed with recommendations for 
future research into the potential cardiovascular benefits of SSRIs and 
serotonin 5HT2A antagonists. 
 
The serotonin theory of platelet-rich thrombus growth 
Platelets are the richest source of serotonin in the body outside the brain.  
The source of the serotonin is extra-platelet, being acquired by means of the 
cell membrane serotonin uptake mechanism.  Inhibition of this mechanism by 
serotonin reuptake inhibitors (SSRIs) causes depletion of platelet serotonin 
[1].  The high concentrations of serotonin located in the dense granules are 
released upon platelet activation, and act upon platelet serotonin 5HT2A 
receptors to activate more platelets, thus constituting a positive feedback or 
“snowball” mechanism leading to thrombus growth.  The serotonin theory [2-5] 
supposes that this serotonin mediation is essential for thrombotic occlusion of 
diseased coronary arteries owing to fact that such occlusion are abolished by 
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antagonism of the platelet 5HT2A receptor [6, 7] even when the major stimulus 
of adrenaline is applied [8] and in the circumstances where thrombolysis has 
failed to clear a complete thrombotic occlusion [9].  Examination of patients 
undergoing angiography showed that a high serotonin level was significantly 
associated with coronary artery disease in patients younger than 70. In nearly 
four years of follow up high serotonin levels were also associated with cardiac 
events. This association persisted after adjustment for conventional risk 
factors [10].  5HT2A antagonism was advocated in the treatment of coronary 
artery disease [11] in which some positive preliminary results were published 
[3]  A further aspect of the theory relevant to such a proposal concerns the 
fact that serotonin is not present in the arterial wall or tissues and does not 
participate in the mediation of haemostatic platelet layers.  Thus, platelet-rich 
thrombus growth which can cause myocardial infarction and unstable angina 
are inhibited, but there are no bleeding side effects as seen with all other anti-
platelet therapies.  However, by chance, the frequent use of SSRIs to treat 
depression after acute coronary syndromes (because other antidepressants 
are cardiotoxic) has led to the realisation that these drugs also reduce the 
consequences of platelet-rich thrombus growth.  In this case, the benefits 
arise from the fact that there is less serotonin in the platelets to be released 
upon activation, and thus there is less serotonin to activate other platelets 
through their 5HT2A receptors. 
 
Figure 1 about here 
 
Serotonin receptors 
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Serotonin is a neurotransmitter in the central nervous system which directly 
activates 5HT receptors.  Serotonin receptors come in 7 types with numerous 
subtypes, most of which are associated with the central nervous system. For 
the purposes of this review we will only examine 5HT1A, 5HT1B, and 5HT2A as 
these are the most important receptors found outside the central nervous 
system, where serotonin acts as a local hormone. The multiplicity of receptor 
subtypes explains the disparate effects of serotonin on the cardiovascular 
system [12]. Serotonin is released into the plasma from nerves, chromaffin 
cells and platelets. It is taken up by liver, endothelium and platelets where it is 
stored in the dense granules (Figure 1). Normal levels of serotonin in plasma 
are very low and at the limits of measurement techniques [13]. Serotonin 
release by platelets is the main source of serotonin in the plasma as the 
platelet contains large amounts of dissolved serotonin; in addition the dense 
granules have a very high concentration of serotonin. The normal adult 
platelet concentration of serotonin is 3.81 ± 0.87 nmoles.109 platelets [14].  
Serotonin is classified as a weak platelet agonist [15] but, when combined 
with other agonists of platelet aggregation, amplifies the response. Local 
concentrations of serotonin in the region of a coronary stenosis, which causes 
shear stress upon the platelet, are very high and form the basis of the 
amplification of the platelet activation and aggregation reactions [16]. See 
Figure 2. 
 
Figure 2 (5ht2) about here 
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Aggregation experiments have shown that the released serotonin from 
platelets interacts with the platelets’ own 5HT2A receptors and that this 
determines the aggregatory response to other agonists; blockade of the 
5HT2A receptor also counteracted aggregation induced by ADP, adrenaline 
and thrombin thus suggesting a major role for serotonin and the platelet 
serotonin receptor in the genesis of intracoronary thrombosis [17]. See Figure 
2. 
 
The role of serotonin in intravascular thrombosis 
 
The beneficial effects of 5HT2A receptor blockade in animal models of 
intracoronary thrombosis have been well shown. Using the Folts model in 
which a critical stenosis overlies damaged endothelium, 5HT2A antagonism 
was effective in abolishing intracoronary platelet-rich thrombosis [6, 7, 18, 19]. 
When used as an adjunct to thrombolysis in the Folts model, selective 5HT2A 
blockade improved flow even after withdrawal of the thrombolytic agent and 
normalisation of coagulation variables and bleeding time, which suggest good 
safety margins as well as therapeutic effectiveness of this class of agents [9]. 
There is also evidence to suggest that ‘demand-induced myocardial 
ischaemia’ in the presence of coronary arterial stenosis, involves platelet 
activation and or microvascular vasoconstriction due to serotonin released 
from platelets [20].  Both recovery of ST segment change and mechanical 
function are improved in the presence of 5HT2A receptor antagonism [20]. The 
presence of circulating platelet aggregates increases in sheep with 
degenerating biological valves but the use of a 5HT2A antagonist dramatically 
decreased the numbers of platelet aggregates [21]. Reports of gastric 
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bleeding associated with the use of SSRI antidepressants [22, 23] consisted 
of 7 isolated case reports [22]. A population-based case-control study has 
shown that SSRIs increase the risk of upper gastrointestinal bleeding by 
threefold. The risk was similar with all the inhibitors confirming that it was a 
class effect and there was a clinically relevant interaction between SSRIs and 
non-steroidal anti-inflammatory drugs.  The conclusions should not be 
accepted without a double blind cross-over placebo controlled clinical trial with 
measurements of bleeding time, especially as major thoracic surgery in 
animals was not accompanied by either clinical bleeding or increased 
bleeding time [9]. 
 
Ketanserin possesses 5HT2A receptor blocking effects as well as α-1 
adrenergic antagonistic properties [24].  Ketanserin has been shown to 
decrease thrombotic complications in peripheral vascular disease [25, 26]. In 
another study of patients awaiting coronary interventions for over one year, 
the effects of prophylaxis by aspirin or ketanserin were compared. The aspirin 
group suffered significantly more infarcts thus indicating a superior protective 
effect of 5HT2A receptor blockade [3]. Unfortunately, ketanserin has 
proarrhythmic properties, when used in combination with potassium-losing 
diuretics, which make it unsuitable for routine clinical use [27] 
 
Role of serotonin in vascular smooth muscle control 
(a) Normal vessels 
Arterial relaxation can be caused by endothelium-independent, or by 
endothelium-dependent, vasodilators. The effect of the latter is to release 
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nitric oxide (NO) which relaxes the vascular smooth muscle. In normal 
circumstances the aggregating platelet releases serotonin which reaches 
5HT1A receptors on the endothelium; this triggers the release of NO leading to 
vascular smooth muscle dilatation. This response contributes to the protective 
function of the intact endothelium in the prevention of unwanted coagulation of 
blood in vessels with a normal intima (Figure 2). Serotonin has, however, 
been shown to be a potent constrictor of epicardial vessels although it has no 
significant effect on resistance vessels when compared with phenylephrine 
[28]. In blood vessels which have suffered endothelial loss and regeneration, 
or arteries which have atherosclerosis, the endothelial secretion of NO is 
considerably reduced which favours the occurrence of vasospasm [29].  In 
patients with vasospastic angina, transcardiac gradients of serotonin were 
significantly higher than those seen in control subjects [30].  
(b) Diseased vessels 
Synergistic vascular contractile effects between serotonin and other 
vasoconstrictor substances within the circulation may play an important role in 
hypertension, peripheral vascular disease and coronary arteries [31]. In 
arteries with evidence of atherosclerosis or dysfunctional endothelium, 
serotonin caused vasoconstriction which could not be prevented by aspirin but 
could be prevented by ketanserin, a drug with 5HT2A receptor blocking 
properties [24]. Patients with coronary artery disease do not possess the 
normal vasodilator response to infused intracoronary serotonin and in patients 
with vasospastic angina, doses of serotonin that dilate normal vessels can 
cause occlusive vasospasm [32].  If the endothelial layer is absent, no NO is 
released and serotonin can reach the 5HT2A receptors of smooth muscle 
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which cause vasoconstriction. Serotonin release by platelets produces a 
positive feedback to promote further platelet activation with more serotonin 
release, vasoconstriction and platelet aggregation (Figure 2). 
The presence of atheroma or other damage to the endothelium augments the 
constrictor response to serotonin [33, 34, 35]. This may be acute or chronic 
with evidence of damaged endothelium possessing a “memory”. Other 
chemical factors such as oxidised low density lipoproteins may also potentiate 
agonist-induced vasoconstriction [36, 37]. The presence of a significant 
coronary artery stenosis exposes further effects of serotonin, namely 
decreased endocardial flow [38], which could be attenuated but not abolished 
by the 5HT1 antagonist methysergide [39]. Serotonin has also been shown to 
constrict intramural penetrating arteries with resultant subendocardial 
ischaemia [40]. Serotonin can constrict coronary collateral vessels which may 
be important in patients with angina where significant portions of the 
myocardium can be collateral-dependent [41]. 
 
 
Fig 3 about here 
 
Long term modification of endothelial responses 
What influence does serotonin have upon the endothelial cell itself? 
Investigators of the mitogenic effect of vasoactive compounds have evaluated 
incubation of serotonin and the stable thromboxane A2 (TXA2) analogue 
U46619 on endothelial cells. U46619 was without effect by itself whereas 
serotonin promoted cell proliferation which was potentiated by U46619 [42]. 
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Interestingly, the mitogenic effect can be blocked by preloading the cells with 
the fish oils eicosapentaenoic acid and docosahexaenoic acid thus providing 
cellular support for the cardiovascular benefits of fish oil in the diet [43]. The 
same investigators have shown that thrombin and serotonin act synergistically 
in promoting vascular smooth muscle proliferation at much lower 
concentrations than each would induce proliferation independently [44]. 
Further work demonstrated that even low concentrations of very low density 
lipoprotein, intermediate density lipoprotein or low density lipoprotein from 
hypercholesterolaemic plasma can significantly potentiate the mitogenic effect 
of serotonin [45]; as serotonin is released in high concentrations by platelets 
at sites of vascular damage this suggests an important mechanism for medial 
thickening. Vascular endothelium seems never to regenerate properly and the 
new endothelium has reduced ability to synthesise NO. In experiments with 
pigs that had coronary endothelial damage, intracoronary serotonin 
repeatedly caused marked vasoconstriction compared to an undamaged 
control artery [46]; in rabbits with carotid endothelial damage, the abilities of 
the vascular smooth muscle were unchanged but endothelium-dependent 
relaxation was severely impaired [47]. This effect has been shown to persist 
for at least three months following endothelial damage [48].  In the isolated 
coronary artery of the dog serotonin causes constriction but 5-
carboxamidotryptamine (a 5HT1 receptor agonist) caused relaxation which 
could be suppressed by removal of the endothelium. In monkey and human 
arterial segments both serotonin and 5-carboxamidotryptamine caused 
contraction [49]. Following focal endothelial loss arteries have been shown to 
have an increased endothelium-dependent constrictor response to serotonin, 
 9
Serotonin Belcher 
but this was not seen with endothelium-independent constrictors such as 
ergonovine, noradrenaline or U46619 [50]. In the diseased human coronary 
artery, the normally endothelium-dependent vasodilators, acetylcholine and 
serotonin, caused vasoconstriction of diseased vessels and also the vessels 
of symptomatic patients who were without obvious coronary artery disease 
[51]. 
 
Genetic studies 
Heightened membrane expression of glycoprotein IIb/IIIa and P-selectin 
receptors, assessed by Western blotting has been previously reported in 
depressed patients without heart disease [52]. There is some evidence for the 
T102C polymorphism as the cause of increased expression of 5HT2A 
receptors; such increased expression is more prevalent in coronary 
thrombosis patients than in controls [53].   Another line of investigation has 
been to look at the serotonin transporter gene which, when it shows 
polymorphism of the promoter region, is associated with raised cholesterol 
levels and cardiovascular disease [54]. This gene has also been shown to 
play a role in susceptibility to coronary artery disease particularly when 
combined with smoking [55].  Though Coto et al were not able to confirm an 
association between and myocardial infarction and 5HT2A receptor gene 
polymorphism, they did find an age-related association between myocardial 
infarction and the homozygous ss deletion of the 5HT transporter gene 
polymorphism [56].  Mutant mice lacking the tph1 gene controlling (with tph2) 
tryptophan hydroxylase (the rate-limiting enzyme for serotonin synthesis) 
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have large hearts and develop heart failure [57].  It is not clear which action of 
the non-neural serotonin system is responsible for this protective effect. 
 
Pharmacology 
(a) General 
The interest in drugs for the prophylaxis of migraine resulted in the production 
of pure 5HT2A antagonists, which turned out to be of no benefit in this 
condition, but are predicted to be of value in intra-arterial thrombosis (see 
section on serotonin theory above). During the period of their development, 
improvements resulted in increased potency of the agents and coincidentally 
an increasing body of evidence that platelets, the vasculature and serotonin 
were implicated in coronary artery disease. 5HT2A antagonists were found to 
have no effect on migraine but 5HT1B/1D agonists such as sumatriptan which 
cause vasoconstriction of the cerebral vasculature are highly effective. They 
do possess minor systemic vasoconstrictor properties [58] and also minor 
constrictor effects on the coronary arteries acting through the 5HT1B subtype 
receptor in people without coronary artery disease [59]. These effects do not 
appear to have any clinical significance but coronary artery or vasospastic 
diseases are contraindications to their use, although Macintyre’s study was in 
patients undergoing diagnostic coronary angiography in which systemic and 
pulmonary artery pressures were raised and coronary artery vasoconstriction 
was seen in response to intravenous sumatriptan; heart rate and ECG 
morphology were unchanged [60].  Studies of receptor sub-types conclude 
that serotonin-induced contraction of coronary arteries is most probably 
mediated via the activation of both 5HT1B and 5HT2A receptors [61, 62]. Chest 
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pain has been reported following administration of sumatriptan-like drugs and 
there have been occasional incidences of myocardial infarction even with 
normal coronaries [63]. However, exercise test abnormalities are rare in 
patients with sumatriptan-induced chest pain [63] and there is little evidence 
of any relation to cardiovascular disease [64]. 
 
(b)  Development of the use of SSRIs in depression following acute 
coronary syndromes 
The older tricyclic antidepressants possess serious cardiovascular side 
effects and are contraindicated in depressed patients with an acute coronary 
syndrome [65]. The use of tricyclic antidepressants, but not SSRIs, is 
associated with an increased risk of myocardial infarction [66, 67]. On the 
other hand, SSRIs are well-established antidepressant drugs that have shown 
little evidence of cardiac toxicity, even in patients with heart disease.  The 
recent Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) 
studied 364 depressed patients with acute coronary syndromes and 
documented no evidence of harm with sertraline treatment and showed a 
(non-significant) trend towards reduction in morbidity and mortality among the 
SSRI-treated patients [68]. Lower cardiovascular morbidity and mortality in 
SSRI-treated patients was reported in recent epidemiologic studies [66, 67, 
68, 69, 70].  Further, a study of 137 post-stroke patients treated with sertraline 
who were followed up for one year also showed reduced mortality and 
morbidity [71]. More trials are required to establish these findings, but should 
not be confined to patients with depression.  Unfortunately, SSRIs take time to 
deplete serotonin from the platelets, so that they cannot be expected to work 
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at once in an acute coronary syndrome, but only by treatment beforehand.  It 
would therefore be necessary to start with trials of secondary prevention by 
SSRIs in patients with arterial disease, whether depressed or not. 
Depression is a significant risk factor for ischæmic heart and cerebrovascular 
disease as well as mortality following myocardial infarction [72, 73]. The 
potential effects of SSRIs upon the cardiovascular system may therefore be 
very important. A recent study [74] draws attention to a potential benefit from 
these drugs in hypertensive patients  18 months after myocardial infarction; 
episodes of depression (negative affect) and hypertensive responses to 
depression were reduced in patients who had been prescribed SSRI drugs. 
The authors ascribed this decreased response to lessened sympathetic drive 
and its effects on cardiovascular reactivity [75, 76], but the investigators did 
not measure catecholamine levels. Unlike ketanserin (with α1 adrenoreceptor 
antagonist properties), pure 5HT2A receptor antagonists do not affect the 
blood pressure although  it is suggested that serotonin may help maintain the 
chronic increase in peripheral resistance in hypertensive patients.  If so, it 
could be due to increased responsiveness of the vessel wall to 5HT1 
serotonin-mediated vasoconstriction, and/or a reduced ability to clear 
serotonin from the blood [29]. Hypertension is, of course, only one of many 
independent risk factors targeted in secondary prevention following 
myocardial infarction. All the patients in the quoted study were also receiving 
aspirin and about half were prescribed ACE inhibitors and/or β-blockers; 80% 
received nitrates which are also known to suppress blood platelets [77]. In 
another hypertension study, blockade of the platelet serotonin receptor (5HT2A 
receptor) with ketanserin in pregnancy, for the treatment of mild to moderate 
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mid-trimester hypertension, decreased the number of cases of pre-eclampsia 
and severe hypertension as well as reducing the incidence of placental 
abruption and perinatal mortality [78]. 
 
Investigation of patients with diabetes and peripheral vascular disease have 
shown low intraplatelet serotonin levels associated with platelet hyper-
reactivity [79], in contrast to the finding of decreased platelet reactivity seen 
with SSRIs [1]. Possibly this is due to over-release of serotonin from activated 
platelets, this was reflected in a 66% increase in plasma serotonin levels 
although these did not reach statistical significance [79]. 
 
Actions of SSRIs in the periphery 
The purpose of SSRI drugs is to increase serotonin concentration in the nerve 
synapses within the central nervous system. This is achieved by prevention of 
reuptake into the nerve terminal and, because of loss of negative feedback 
control, there is overproduction of serotonin by the nerve terminal [80] 
Blood platelets actively take up serotonin from the plasma but are incapable 
of its synthesis. SSRI drugs reduce the uptake of tritiated serotonin by 
platelets [81].  This has led to the use of blood platelets as a surrogate for the 
central nervous system in the study of these drugs [82]. The tricyclic 
antidepressants such as imipramine have been reported to decrease platelet 
serotonin concentration but do not inhibit uptake [83].  In a general practice 
study, in which normal patients were compared to depressive patients, those 
taking the SSRI drug fluoxetine had significantly decreased aggregatory 
response to submaximal collagen stimulation [1]; this study also showed a 
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significant decrease in serotonin concentration in platelet rich plasma 
associated with use of fluoxetine but not with the tricyclic antidepressant 
amitryptiline. It is attractive to suggest that lowered platelet serotonin content 
translates into less serotonin release during platelet activation at an 
intracoronary stenosis. A study into the effects of paroxetine (SSRI) revealed 
lower platelet factor 4 (PF4) and β-thromboglobulin (ß-TG) levels and 
suggests that reduced platelet aggregation in vivo may positively impact upon 
coronary artery disease-related mortality in this [84]. 
 
Is the mechanism of beneficent action of SSRIs in coronary disease 
platelet related? 
Enhanced platelet activation has indeed been proposed as a possible 
mechanism contributing to the increased cardiac risk associated with the 
diagnosis of major depression [85, 86].  Circumstantial evidence is consistent 
with this prediction.  Data have accumulated indicating that depression is 
associated with platelet activation and that the SSRIs [1, 85, 86] affect platelet 
function.  SSRIs reduce platelet activity in patients on aspirin therapy and in 
patients with heart failure [87]. Platelet activity is also decreased by in vitro 
exposure to both sertraline (an SSRI) and N-desmethylsertraline, the non-
active metabolite of sertraline [88].  Does this imply an effect on platelets 
which is not dependent on serotonin depletion?  Paroxetine reduces the 
abnormality in platelet hyper-reactivity observed in depressed patients [89]. 
Patients with major depression exhibit reduction of serotonin transporter 
platelet binding sites by imipramine [90, 91] and an increase in serotonin 
5HT2A receptor binding sites on the platelet surface [92], as determined by 
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radioligand binding studies [93].  Enhanced platelet activity is also reflected in 
markedly elevated β-TG and PF4 levels in patients suffering from depression 
and chronic ischemic heart disease [94]. The breakdown of serotonin is 
dependent on monoamine oxidase, which is increased in depressed patients 
[95]. Unfortunately, for the clarity of interpretation of modern studies, most 
patients with acute coronary syndromes are treated with aspirin and/or 
clopidogrel, but the accumulated evidence is strongly consistent with platelet 
activation as a major determinant of increased intra-arterial thrombosis in 
depressed patients. 
   
Can SSRIs reverse platelet activation in patients with arterial disease? 
A number of studies have been carried out using the SSRI sertraline which is 
a potent SSRI and a selective dose-related inhibitor of the serotonin 
transporter; by this mechanism serotonin 5-HT2A receptors and other 
serotonin receptors in the brain are downregulated [96].  As with fluoxetine [1], 
sertraline depletes platelet serotonin [82]. There is also a reduction in SSRI 
radioligand binding [97]. Overall platelet thrombosis as determined in vitro by 
collagen stimulation is inhibited by sertraline [98], as is intracellular Ca2+ 
mobilisation [99].  A recent study assessed both platelet and endothelial 
markers in a post-acute coronary syndrome patient group in whom 89% 
received aspirin and 17% received clopidogrel or ticlopidine, while 29% 
received either warfarin or coumadin. In a double-blind comparison of 
sertraline and placebo, 6 or 16 weeks of sertraline treatment caused 
significantly greater reductions in β-Thromboglobulin, in spite of the 
concomitant antithrombotic therapy [86].  The differences were detectable 
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against a background of decreasing activation in the placebo group as a result 
of recovery from an acute coronary syndrome.  Moreover, markers of 
endothelial function such as PECAM-1, 6-oxo-PGF1α and VCAM-1 were 
unaffected, in line with the non-participation of vessel wall components in the 
serotonin theory (see above). The falls in PF4 and TXA2 following acute 
coronary syndromes were similar in treated and placebo groups.  In view of 
the opinion that β-Thromboglobulin and PF4 are inadequate descriptors of 
platelet function, and that the samples were collected in citrate (which 
involves unphysiologically low extracellular Ca2+ concentration) it would be 
worthwhile to repeat this study with measurements of platelet IIb/IIIa binding 
to fibrinogen in hirudinised samples. 
 
Clinical platelet function testing 
Clinical platelet function testing has been fraught with difficulty, but in view of 
the importance of platelet function in assessment and prognosis, some 
attempt should be made to standardise methods.  Vacutainer® sampling is 
unsuitable as suction from a vein through a small bore needle will activate the 
platelet artefactually.  There is considerable disparity in techniques of 
assessing platelet function. Because of the importance of serotonin in the 
development and amplification of the platelet aggregatory response, we 
attempted to mimic the clinical situation as closely as possible by using 
normocalcæmic whole blood. To maintain normocalcæmia the anticoagulant 
used is recombinant hirudin; this is a pure thrombin inhibitor which has no 
intrinsic anti-platelet activity and has been shown to be ineffective when 
platelets are under conditions of high shear and exposed to collagen [100].  
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The advantage of normocalcæmia is because low Ca++ concentration favours 
TXA2 production and TXA2-dependent secretion during aggregation induced 
by weak agonists such as ADP or adrenaline [101,102, 103, 104]. TXA2 
production causes additional platelet stimulation and aggregation by positive 
feedback and thus aggregatory responses in acalcaemic conditions can be 
spurious. The technique we employ uses low dose (sub-maximal) collagen as 
the agonist; this simulates the exposure of subendothelial collagen in the 
damaged vessel wall. At normocalcæmia it has been shown that TXA2 
formation and release of ADP and serotonin largely account for platelet 
aggregation with collagen in vitro, as determined by platelet counting [105]. 
Thus, collagen provides a global means of assessing impairment in vitro since 
these mediators may be altered through several different mechanisms or 
changes in expression of the integrin receptors involved in adhesion and 
aggregation, as well as changes in platelet sensitivity to TXA2, ADP and 
adrenaline [105]. This technique has also been applied to investigation of the 
heparin-induced platelet dysfunction which is encountered clinically and has 
been demonstrated to be a failure to form large stable aggregates, despite 
microaggregation being unaffected [106, 107, 108, 109, 110].  Single platelet 
counting is labour intensive, but many of the simpler tests are unsatisfactory.   
Binding of the platelet IIb/IIIa receptor to fibrinogen can be measured using 
cell cytometry or an automated fibrinogen-binding test using the Ultegra® 
rapid platelet function assay (Accumetrics, San Diego, CA, USA).  
Unfortunately, these assays have not been used so far with samples 
anticoagulated with hirudin to maintain normocalcaemia, although there 
appears to be no technical difficulty in so doing. 
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The future 
To where should research into the effects of SSRIs on patients with vascular 
disease lead? 
 
Figure 4 about here 
 
What is the potential for therapeutic intervention involving the serotonin 
system in non-depressed patients with arterial disease? 
Recent confirmation that acute events are associated with activation of the 
platelet serotonin system was obtained from the fact that excessive 
transcardiac accumulation of serotonin appears to play a role in the 
conversion of chronic stable angina to an unstable coronary syndrome [10]. 
Blockade of this system during acute coronary syndromes (or acute limb 
ischaemia) is therefore an obvious therapeutic intervention to be tried.  In view 
of the time required for SSRIs to achieve antiplatelet effects in acute coronary 
syndromes, it may be difficult to obtain ethical clearance for a comparison of 
these agents with those that block the serotonin system directly. 
In view of the lower platelet serotonin levels reported with SSRI treatment, the 
evidence of decreased platelet aggregability and the decreased hypertensive 
responses seen with the use of SSRIs, three lines of research open up: 
1. First, monitoring of cardiovascular events should be possible in these 
patients and can be related to the drugs’ antihypertensive effects. 
2. Second, the antiplatelet effects of these drugs should be monitored and 
compared to patients not taking SSRIs. It is now possible reliably to 
 19
Serotonin Belcher 
measure platelet function in whole blood 24 hours after sampling; this 
would allow remote testing of a large number of patients [111, 112]. 
3. Third, the possibility of interactions with aspirin and stomach bleeding 
merits further investigation. It may be that the withdrawal of aspirin could 
be carried out safely in these patients who would remain protected by their 
SSRI drug. This of course could be tested by the platelet aggregometry 
technique as described in the section above. 
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